Steen Lisby Net Worth

Steen Lisby biography

Dr. Steen Lisby M.D. serves as Senior Vice President, Chief Medical Officer of the Company. Dr. Lisby joined our Company in June 2017 as our Senior Vice President and Chief Medical Officer. Dr. Lisby has extensive clinical and scientific experience, and is the author of over 50 scientific peer-reviewed publications in clinical research. Previously, Dr. Lisby was Vice President, Head of Medical at Genmab A/S from 2014 to 2017 and also held other positions there including Senior Medical Director from 2010 to 2014, Medical Director from 2008 to 2010 and Medical Advisor from 2004 to 2007. Dr. Lisby received his M.D. degree from the University of Copenhagen and is a named inventor on seven patent applications.

How old is Steen Lisby?

Steen Lisby is 56, he's been the Senior Vice President e Chief Medical Officer of Y-Mabs Therapeutics Inc since 2017. There are 7 older and 12 younger executives at Y-Mabs Therapeutics Inc. The oldest executive at Y-Mabs Therapeutics Inc is Dr. Torben Lund-Hansen, 70, who is the Sr. VP & Chief Technical Officer.

What's Steen Lisby's mailing address?

Steen's mailing address filed with the SEC is C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK, NY, 10169.

Insiders trading at Y-Mabs Therapeutics Inc

Over the last 6 years, insiders at Y-Mabs Therapeutics Inc have traded over $85,284,951 worth of Y-Mabs Therapeutics Inc stock and bought 1,819,126 units worth $23,554,756 . The most active insiders traders include James Healy, Thomas Gad, eJohan Wedell Wedellsborg. On average, Y-Mabs Therapeutics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $494,414. The most recent stock trade was executed by Torben Lund Hansen on 28 August 2024, trading 50,000 units of YMAB stock currently worth $219,000.

What does Y-Mabs Therapeutics Inc do?

y-mabs is late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. the company has a broad and advanced product pipeline, including 2 pivotal-stage product candidates - naxitamab and omburtamab - which target tumors that express gd2 and b7-h3, respectively. our mission is to become the world leader in developing antibody-based cancer products that address clear unmet needs in pediatric oncology. with the right partnerships and collaboration, we envision expanding our capabilities to treat adults - changing the course of cancer and its outcome.

Y-Mabs Therapeutics Inc executives and stock owners

Y-Mabs Therapeutics Inc executives and other stock owners filed with the SEC include:

• Dr. Claus Juan Møller San Pedro M.D., Ph.D.,
  CEO & Director
• Claus Moller-San Pedro,
  Chief Executive Officer, Director
• Thomas Gad,
  Chairman of the Board, President, Founder, Head of Business Development and Strategy
• Thomas Gad,
  Founder, Chairman, Pres and Head of Bus. Devel. & Strategy
• Bo Kruse,
  Chief Financial Officer, Executive Vice President, Treasurer, Secretary, Director
• Bo Kruse,
  Exec. VP, Sec., Treasurer & CFO
• David Gill,
  Independent Director
• James Healy,
  Independent Director
• Ashutosh Tyagi,
  Independent Director
• Gerard Ber,
  Independent Director
• Johan Wedell-Wedellsborg,
  Independent Director
• Torben Lund-Hansen,
  Senior Vice President, Chief Technical Officer
• Steen Lisby,
  Senior Vice President, Chief Medical Officer
• Philip Herman,
  Senior Vice President and Chief Commercial Officer
• Mahiuddin Ahmed,
  Senior Vice President, Chief Scientific Officer
• Joris Wilms,
  Chief Operating Officer, Senior Vice President
• Sue Smith,
  Sr. VP & Chief Commercial Officer
• Dr. Torben Lund-Hansen,
  Sr. VP & Chief Technical Officer
• Joris Wiel Jan Wilms,
  Sr. VP & COO
• Dr. Vignesh Rajah,
  Sr. VP & Chief Medical Officer
• Dr. Steen Lisby M.D., M.Sc.,
  Sr. VP & Chief Scientific Officer
• Peter P. Pfreundschuh,
  CFO and Treasurer
• Gregory S Raskin,
  Director
• Ashu Tyagi,
  Director
• Mary Tagliaferri,
  Director
• Laura Hamill,
  Director
• Vignesh Rajah,
  SVP & CHIEF MEDICAL OFFICER
• Biotech Ap S Wg,
  Director
• Susan Laura Smith,
  SVP & CHIEF COMMERCIAL OFFICER
• Michael J Rossi,
  PRESIDENT & CEO